Teaching AI the biology of antibodies speeds drug discovery
Designing an effective antibody drug is like searching for the right key in a warehouse of locks. Scientists may begin with millions—or even billions—of antibody candidates, but only a tiny fraction will recognize and bind tightly to the disease target. Identifying those rare candidates has long been one of the biggest challenges in developing antibody medicines.
Designing an effective antibody drug is akin to searching for the right key in a warehouse of locks. Identifying those rare candidates has long been a major challenge in developing antibody medicines. A team of researchers at Boston University has developed an AI framework specifically tailored to antibodies, significantly narrowing down the search.
Instead of treating antibodies as generic proteins, the researchers created an antibody-specific language model that learns the fundamental patterns in the regions responsible for antigen binding. By focusing on these small regions of antibodies, known as complementarity-determining regions (CDRs), the AI model can identify the most promising therapeutic candidates before they enter the laboratory.
This focused approach has led to improvements in binding affinity prediction by up to 27%, while requiring fewer computational resources than other existing antibody AI models. The study, published in the journal Communications AI & Computing, highlights the potential of this novel approach in accelerating antibody optimization and reducing the time, labor, and cost associated with the discovery process.
Written by urgent.news from Phys.org's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
